TITAN PHARMACEUTICALS INC: Nasdaq/NYSE listing notice — Titan Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M

TITAN PHARMACEUTICALS INC

Stockholders' equity of $1.363M as of Dec 31, 2022, below Nasdaq's $2.5M minimum.
Company has 45 days to submit a compliance plan; may get up to 180 days to cure.
2022 annual meeting set for June 19, 2023; record date May 1, 2023.
Shareholder proposals due by April 24, 2023 for inclusion in proxy materials.
Listing on Nasdaq Capital Market unaffected for now while company evaluates options.

item 3.01 item 5.08 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000. In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy Nasdaq Marketplace Rule 5550(b)(1). The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. In

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001829126-23-002648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.